Optimizing the exercise prescription for depression: The search for biomarkers of response

Current Opinion in Psychology

Volumn 4, Issue , 2015, Pages 43-47

  Medina, Johnna L ^a   Jacquart, Jolene ^a   Smits, Jasper A J ^a  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84923673415     PISSN: 2352250X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.copsyc.2015.02.003     Document Type: Review

References (61)

1. Toups M., Trivedi M.H. Biomarkers and the future of treatment for depression. Cerebrum 2012, 2012.
2. Rush A.J., Trivedi M.H., Wisniewski S.R., Nierenberg A.A., Stewart J.W., Warden D., Niederehe G., Thase M.E., Lavori P.W., Lebowitz B.D., et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 2006, 163:1905-1917.
3. Rush A.J., Trivedi M.H., Wisniewski S.R., Stewart J.W., Nierenberg A.A., Thase M.E., Ritz L., Biggs M.M., Warden D., Luther J.F., et al. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med 2006, 354:1231-1242.
4. Rimer J., Dwan K., Lawlor D.A., Greig C.A., McMurdo M., Morley W., Mead G.E. Exercise for depression. Cochrane Database Syst Rev 2012, 7:CD004366.
5. Josefsson T., Lindwall M., Archer T. Physical exercise intervention in depressive disorders: meta-analysis and systematic review. Scand J Med Sci Sports 2014, 24:259-272.
6. Mota-Pereira J., Silverio J., Carvalho S., Ribeiro J.C., Fonte D., Ramos J. Moderate exercise improves depression parameters in treatment-resistant patients with major depressive disorder. J Psychiatr Res 2011, 45:1005-1011.
7. Stathopoulou G., Powers M.B., Berry A.C., Smits J.A.J., Otto M.W. Exercise interventions for mental health: a quantitative and qualitative review. Clin Psychol Sci Pract 2006, 13:179-193.
8. Stanton R., Reaburn P. Exercise and the treatment of depression: a review of the exercise program variables. J Sci Med Sport 2014, 17:177-182.
9. Cooney G.M., Dwan K., Greig C.A., Lawlor D.A., Rimer J., Waugh F.R., McMurdo M., Mead G.E. Exercise for depression. Cochrane Database Syst Rev 2013, 9:CD004366.
10. Dunn A.L., Trivedi M.H., Kampert J.B., Clark C.G., Chambliss H.O. Exercise treatment for depression: efficacy and dose response. Am J Prev Med 2005, 28:1-8.
11. DiMatteo M.R., Lepper H.S., Croghan T.W. Depression is a risk factor for noncompliance with medical treatment: meta-analysis of the effects of anxiety and depression on patient adherence. Arch Intern Med 2000, 160:2101-2107.
12. Kangas J.L., Baldwin A.S., Rosenfield D., Smits J.A.J., Rethorst C.D. Examining the moderating effect of depressive symptoms on the relation between exercise and self-efficacy during the initiation of regular exercise. Health Psychol 2014, 10.1037/hea0000142.
13. Chalder M., Wiles N.J., Campbell J., Hollinghurst S.P., Haase A.M., Taylor A.H., Fox K.R., Costelloe C., Searle A., Baxter H., et al. Facilitated physical activity as a treatment for depressed adults: randomised controlled trial. BMJ 2012, 344:e2758.
14. Dowlati Y., Herrmann N., Swardfager W., Liu H., Sham L., Reim E.K., LanctÔt K.L. A meta-analysis of cytokines in major depression. Biol Psychiatry 2010, 67:446-457.
15. Liu Y., Ho R.C.-M., Mak A. Interleukin (IL)-6, tumour necrosis factor alpha (TNF-α) and soluble interleukin-2 receptors (sIL-2R) are elevated in patients with major depressive disorder: a meta-analysis and meta-regression. J Affect Disord 2012, 139:230-239.
16. Zhao G., Ford E.S., Li C., Tsai J., Dhingra S., Balluz L.S. Waist circumference, abdominal obesity, and depression among overweight and obese U.S. adults: national health and nutrition examination survey 2005-2006. BMC Psychiatry 2011, 11:130.
17. Faith M.S., Butryn M., Wadden T.A., Fabricatore A., Nguyen A.M., Heymsfield S.B. Evidence for prospective associations among depression and obesity in population-based studies. Obes Rev 2011, 12:e438-e453.
18. Howren M.B., Lamkin D.M., Suls J. Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom Med 2009, 71:171-186.
19. Mesquita A.R., Correia-Neves M., Roque S., Castro A.G., Vieira P., Pedrosa J., Palha J.A., Sousa N. IL-10 modulates depressive-like behavior. J Psychiatr Res 2008, 43:89-97.
20. Dhabhar F.S., Burke H.M., Epel E.S., Mellon S.H., Rosser R., Reus V.I., Wolkowitz O.M. Low serum IL-10 concentrations and loss of regulatory association between IL-6 and IL-10 in adults with major depression. J Psychiatr Res 2009, 43:962-969.
21. Hiles S.A., Baker A.L., de Malmanche T., Attia J. A meta-analysis of differences in IL-6 and IL-10 between people with and without depression: exploring the causes of heterogeneity. Brain Behav Immun 2012, 26:1180-1188.
22. Kaster M.P., Gadotti V.M., Calixto J.B., Santos A.R.S., Rodrigues A.L.S. Depressive-like behavior induced by tumor necrosis factor-α in mice. Neuropharmacology 2012, 62:419-426.
23. Dantzer R., O'Connor J.C., Freund G.G., Johnson R.W., Kelley K.W. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci 2008, 9:46-56.
24. Raison C.L., Borisov A.S., Woolwine B.J., Massung B., Vogt G., Miller A.H. Interferon-alpha effects on diurnal hypothalamic-pituitary-adrenal axis activity: relationship with proinflammatory cytokines and behavior. Mol Psychiatry 2010, 15:535-547.
25. Juengling F.D., Ebert D., Gut O., Engelbrecht M.A., Rasenack J., Nitzsche E.U., Bauer J., Lieb K. Prefrontal cortical hypometabolism during low-dose interferon alpha treatment. Psychopharmacology (Berl) 2000, 152:383-389.
26. Capuron L., Pagnoni G., Demetrashvili M., Woolwine B.J., Nemeroff C.B., Berns G.S., Miller A.H. Anterior cingulate activation and error processing during interferon-alpha treatment. Biol Psychiatry 2005, 58:190-196.
27. Raison C.L., Capuron L., Miller A.H. Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol 2006, 27:24-31.
28. Fragala M.S., Kraemer W.J., Denegar C.R., Maresh C.M., Mastro A.M., Volek J.S. Neuroendocrine-immune interactions and responses to exercise. Sports Med 2011, 41:621-639.
29. Silverman M.N., Deuster P.A. Biological mechanisms underlying the role of physical fitness in health and resilience. Interface Focus 2014, 4:20140040.
30. Rethorst C.D., Moynihan J., Lyness J.M., Heffner K.L., Chapman B.P. Moderating effects of moderate-intensity physical activity in the relationship between depressive symptoms and interleukin-6 in primary care patients. Psychosom Med 2011, 73:265-269.
31. Eyre H., Baune B.T. Neuroimmunological effects of physical exercise in depression. Brain Behav Immun 2012, 26:251-266.
32. Eyre H.A., Papps E., Baune B.T. Treating depression and depression-like behavior with physical activity: an immune perspective. Front Psychiatry 2013, 4:3.
33. Kohut M.L., McCann D.A., Russell D.W., Konopka D.N., Cunnick J.E., Franke W.D., Castillo M.C., Reighard A.E., Vanderah E. Aerobic exercise, but not flexibility/resistance exercise, reduces serum IL-18, CRP, and IL-6 independent of beta-blockers, BMI, and psychosocial factors in older adults. Brain Behav Immun 2006, 20:201-209.
34. Panagiotakos D.B., Pitsavos C., Chrysohoou C., Kavouras S., Stefanadis C. The associations between leisure-time physical activity and inflammatory and coagulation markers related to cardiovascular disease: the ATTICA study. Prev Med 2005, 40:432-437.
35. Smith J., Dykes R., Douglas J.E., Krishnaswamy G., Berk S. Long-term exercise and atherogenic activity of blood mononuclear cells in persons at risk of developing ischemic heart disease. JAMA 1999, 281:1722-1727.
36. Tiemeier H., Hofman A., van Tuijl H.R., Kiliaan A.J., Meijer J., Breteler M.M.B. Inflammatory proteins and depression in the elderly. Epidemiology 2003, 14:103-107.
37. Hannestad J., DellaGioia N., Bloch M. The effect of antidepressant medication treatment on serum levels of inflammatory cytokines: a meta-analysis. Neuropsychopharmacology 2011, 36:2452-2459.
38. Eller T., Vasar V., Shlik J., Maron E. Pro-inflammatory cytokines and treatment response to escitalopram in major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2008, 32:445-450.
39. Trivedi M.H., Greer T.L., Church T.S., Carmody T.J., Grannemann B.D., Galper D.I., Dunn A.L., Earnest C.P., Sunderajan P., Henley S.S., et al. Exercise as an augmentation treatment for nonremitted major depressive disorder: a randomized, parallel dose comparison. J Clin Psychiatry 2011, 72:677-684.
40. Rethorst C.D., Toups M.S., Greer T.L., Nakonezny P.A., Carmody T.J., Grannemann B.D., Huebinger R.M., Barber R.C., Trivedi M.H. Pro-inflammatory cytokines as predictors of antidepressant effects of exercise in major depressive disorder. Mol Psychiatry 2013, 18:1119-1124.
41. Barde Y.A. Neurotrophic factors: an evolutionary perspective. J Neurobiol 1994, 25:1329-1333.
42. Levi-Montalcini R. The nerve growth factor 35 years later. Science 1987, 237:1154-1162.
43. Krishnan V., Nestler E.J. The molecular neurobiology of depression. Nature 2008, 455:894-902.
44. Karege F., Perret G., Bondolfi G., Schwald M., Bertschy G., Aubry J.-M. Decreased serum brain-derived neurotrophic factor levels in major depressed patients. Psychiatry Res 2002, 109:143-148.
45. Molendijk M.L., Spinhoven P., Polak M., Bus B.a., Penninx A., Elzinga B.W.J.H.B.M. Serum BDNF concentrations as peripheral manifestations of depression: evidence from a systematic review and meta-analyses on 179 associations (N=9484). Mol Psychiatry 2014, 19:791-800.
46. Polyakova M., Stuke K., Schuemberg K., Mueller K., Schoenknecht P., Schroeter M.L. BDNF as a biomarker for successful treatment of mood disorders: a systematic & quantitative meta-analysis. J Affect Disord 2015, 174:432-440.
47. Shirayama Y., Chen A.C.-H., Nakagawa S., Russell D.S., Duman R.S. Brain-derived neurotrophic factor produces antidepressant effects in behavioral models of depression. J Neurosci 2002, 22:3251-3261.
48. Schmidt H.D., Duman R.S. Peripheral BDNF produces antidepressant-like effects in cellular and behavioral models. Neuropsychopharmacology 2010, 35:2378-2391.
49. Adlard P.A., Cotman C.W. Voluntary exercise protects against stress-induced decreases in brain-derived neurotrophic factor protein expression. Neuroscience 2004, 124:985-992.
50. Marais L., Stein D.J., Daniels W.M.U. Exercise increases BDNF levels in the striatum and decreases depressive-like behavior in chronically stressed rats. Metab Brain Dis 2009, 24:587-597.
51. Heyman E., Gamelin F.-X., Goekint M., Piscitelli F., Roelands B., Leclair E., Di Marzo V., Meeusen R. Intense exercise increases circulating endocannabinoid and BDNF levels in humans-possible implications for reward and depression. Psychoneuroendocrinology 2012, 37:844-851.
52. Szuhany K.L., Bugatti M., Otto M.W. A meta-analytic review of the effects of exercise on brain-derived neurotrophic factor. J Psychiatr Res 2015, 60:56-64.
53. Toups M.S.P., Greer T.L., Kurian B.T., Grannemann B.D., Carmody T.J., Huebinger R., Rethorst C., Trivedi M.H. Effects of serum brain derived neurotrophic factor on exercise augmentation treatment of depression. J Psychiatr Res 2011, 45:1301-1306.
54. Salehi I., Hosseini S.M., Haghighi M., Jahangard L., Bajoghli H., Gerber M., Pühse U., Kirov R., Holsboer-Trachsler E., Brand S. Electroconvulsive therapy and aerobic exercise training increased BDNF and ameliorated depressive symptoms in patients suffering from treatment-resistant major depressive disorder. J Psychiatr Res 2014, 57:117-124.
55. Audet M.-C., Anisman H. Interplay between pro-inflammatory cytokines and growth factors in depressive illnesses. Front Cell Neurosci 2013, 7:68.
56. Egan M.F., Kojima M., Callicott J.H., Goldberg T.E., Kolachana B.S., Bertolino A., Zaitsev E., Gold B., Goldman D., Dean M., et al. The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell 2003, 112:257-269.
57. Chen Z.-Y., Jing D., Bath K.G., Ieraci A., Khan T., Siao C.-J., Herrera D.G., Toth M., Yang C., McEwen B.S., et al. Genetic variant BDNF (Val66Met) polymorphism alters anxiety-related behavior. Science 2006, 314:140-143.
58. Mata J., Thompson R.J., Gotlib I.H. BDNF genotype moderates the relation between physical activity and depressive symptoms. Health Psychol 2010, 29:130-133.
59. Bryan A., Hutchison K.E., Seals D.R., Allen D.L. A transdisciplinary model integrating genetic, physiological, and psychological correlates of voluntary exercise. Health Psychol 2007, 26:30-39.
60. Kenis G., Prickaerts J., van Os J., Koek G.H., Robaeys G., Steinbusch H.W.M., Wichers M. Depressive symptoms following interferon-α therapy: mediated by immune-induced reductions in brain-derived neurotrophic factor?. Int J Neuropsychopharmacol 2011, 14:247-253.
61. Calabrese F., Rossetti A.C., Racagni G., Gass P., Riva M.A., Molteni R. Brain-derived neurotrophic factor: a bridge between inflammation and neuroplasticity. Front Cell Neurosci 2014, 8:430.